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Abstract
The yeast Saccharomyces cerevisiae is widely used in baking, brewing, wine making, and biotechnology and previously has had GRAS
(generally regarded as safe) status. Recent evidence indicates the involvement of S. cerevisiae in a range of superficial and systemic diseases.
Numerous cases of S. cerevisiae-induced vaginitis have been documented as have cases of oropharyngeal infection. Potentially fatal
systemic disease due to S. cerevisiae has been recorded in bone marrow transplant patients and in those immunocompromised as a result
of cancer or AIDS. A number of studies have indicated that commercially available strains of S. cerevisiae may cause disease in certain
individuals. Pathogenic isolates exhibit the ability to grow at 42°C, produce proteinase, and are capable of pseudohyphal growth. In addition,
a number of isolates are capable of phenotypic switching and show partial or complete resistance to commonly used antifungal agents,
including fluconazole. In the light of these findings, S. cerevisiae should now be regarded as an opportunistic pathogen, albeit of relatively
low virulence, and treated accordingly by those in the industrial and biotechnological sectors. © 1999 Elsevier Science Inc. All rights
reserved.
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1. Saccharomyces cerevisiae: friend or foe?
The saprophytic yeast S. cerevisiae is widely distributed
in nature and has been used extensively since the dawn of
civilization. Until recent times the primary use of this yeast
has been in the production of bread (baker’s yeast) and
alcoholic beverages (brewer’s yeast). It is also frequently
ingested as a dietary supplement or inadvertently as a con-
taminant of food products.
S. cerevisiae has become increasingly important over
recent years in biotechnology and is now one of the most
studied and best characterized organisms on the planet. It
has been used as a model eukaryote for some time and is an
excellent model for studies on mitochondrial form and func-
tion. S. cerevisiae has been used extensively in the biotech-
nology sector as a cloning vector (single or multicopy). One
advantage of using S. cerevisiae is that proteins can be
secreted into the growth medium or anchored in the cell
wall of the yeast, as in the case of the -galactosidase--
agglutinin (Gal-AC1) fusion protein [1]. The amount of
fusion protein present on the yeast cell surface is dependent
on the copy number of the construct used. S. cerevisiae is
used to produce small hepatitis B surface proteins for use in
hepatitis B vaccines, and production of the proteins is high-
est for those cells containing a high multicopy plasmid [2].
S. cerevisiae is also used to mass-produce the interferon
class of immune cytokines, which are important in the
regulation of immune responses to certain diseases. For
example, interferon  is important in the treatment of cer-
tain cancers, in particular lymphomas such as Kaposi’s
sarcoma [3,4], and interferon  is used in combination with
antimicrobials in order to prevent the recurrence of some
infections [5,6].
There are many reasons for the widespread use of S.
cerevisiae in the biotechnology sector. Culturing the yeast is
inexpensive and relatively easy. S. cerevisiae has always
had “generally regarded as safe” status and can, therefore,
legally be used in the food and pharmacological sector [1].
However, numerous cases of clinical infection caused by S.
cerevisiae have been reported in the literature in recent
years. Classically, S. cerevisiae has been regarded as non-
pathogenic, but recent evidence indicates that some isolates
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are virulent and have been implicated in the induction of
disease, particularly in immunocompromised individuals. In
Europe, S. cerevisiae has been upgraded from “generally
regarded as safe” to Biosafety level one [7], indicating the
ability to cause superficial or mild systemic infections. This
finding will have profound implications for the continued
use of this yeast, particularly in situations where prolonged
contact with susceptible hosts is a possibility. S. cerevisiae
should now be regarded as an opportunistic pathogen of low
virulence rather than as a nonpathogenic yeast.
This review will examine cases of S. cerevisiae-induced
disease, identify the virulence factors of pathogenic isolates,
and discuss the ability of the yeast to resist conventional
antifungal agents. Current therapy and possible future alter-
natives will be examined. The potential dangers and impli-
cations of the continued use of S. cerevisiae in the biotech-
nology sector will be assessed.
2. S. cerevisiae-induced disease
Although frequently encountered as a harmless body,
commensal S. cerevisiae has been implicated in the induc-
tion of disease in a number of instances. It would appear that
S. cerevisiae is exploiting the increased numbers of patients
immunocompromised as a result of disease or therapy rather
than exhibiting enhanced levels of virulence. A review of
the medical literature indicates that S. cerevisiae isolates
have been responsible for a variety of diseases ranging from
superficial to life-threatening, systemic infections. Infec-
tions due to S. cerevisiae have been recorded in patients
showing no obvious predisposing factor(s) [8,9] but also in
those severely immunocompromised as a result of disease
(e.g. AIDS, malignancy, diabetes) or therapeutic proce-
dure(s) (e.g. broad spectrum antibiotic therapy, organ trans-
plantation). The reported extent of S. cerevisiae-induced
disease is probably an underestimate of the true situation
due to a continuing belief by many in the medical profession
that this yeast is nonpathogenic [8]. In addition, there is a
tendency to arbitrarily identify any yeast isolated from clin-
ical samples as belonging to the genus Candida rather than
pursuing the identification to reveal the real culprit [9,10].
3. Superficial S. cerevisiae disease
Yeast-induced vaginitis affects approximately 75% of
women at some point in their life, and a subpopulation of
between 5% and 12% suffer from recurrent bouts of infec-
tion that may persist for months or, in severe cases, years
[11]. Candida albicans is responsible for 85–90% of cases
of this condition, with the remaining cases being due to a
range of other Candida species. In a survey of the yeasts
responsible for this condition in 2000 women, S. cerevisiae
was identified as the causative agent in only nine cases
(0.45% of the sample population) [9], and another survey
reported an incidence of 1.06% in a patient population of
750 [12]. Other reports have identified S. cerevisiae as the
etiologic agent in 0.45–0.7% of cases [11,13]. One study
identified the presence of S. cerevisiae in 5.4% of women
presenting with symptoms of vaginitis and in 19.7% of
asymptomatic women [14]. Although it must be stated,
there was no evidence in this case that S. cerevisiae was the
sole yeast responsible for the condition. In many cases
where vaginitis was caused by this yeast, recurrent bouts of
infection were noted. It was also observed that S. cerevisiae
was frequently isolated in association with Candida gla-
brata, another vaginal pathogen, or following a bout of
vaginitis induced by this latter yeast that may indicate that
the two yeasts coexist as pathogens in the vagina [9]. Pa-
tients presenting with S. cerevisiae-induced vaginitis
showed no apparent predisposing factors, while a number of
patients had local disease or other predisposing conditions
that may have facilitated the growth of the yeast [9].
While S. cerevisiaemay be found as a normal component
of the gastrointestinal tract in humans, and transmission
from this site to the female genital tract may occur, exog-
enous infection with S. cerevisiae has been documented. S.
cerevisiae-induced vaginitis has been recorded in women
whose partners worked in bakeries or pizzeria. Electro-
phoretic karyotyping of yeasts isolated from the vagina, the
hands of the patient’s husbands, and the yeasts used in the
pizzeria revealed the presence of the same strain [12]. It was
suggested that overexposure to this yeast resulted in vaginal
colonization and infection. There are no reports in the lit-
erature of cases of S. cerevisiae-induced vaginitis in women
working in bakeries who would be exposed to huge amounts
of the yeast on a daily basis, although this condition has
been linked to the use of S. cerevisiae in home baking [13].
Restriction enzyme analysis of isolates of S. cerevisiae
responsible for vaginitis by using EcoRI indicated that ge-
netically indistinguishable isolates were responsible for in-
fection in nonrelated groups of women [13]. A number of
strains were identical to yeasts commercially available for
baking, again indicating the possibility of exogenous infec-
tion of the vagina. Some S. cerevisiae isolates implicated in
the induction of vaginitis could be divided into two subtypes
based upon the presence or absence of a 3-kb fragment upon
agarose gel electrophoresis [15].
4. Systemic S. cerevisiae disease
S. cerevisiae-induced vaginitis may be unpleasant, and at
times difficult to treat due to the inherent drug resistance of
certain isolates, but it is not life threatening except in se-
verely immunocompromised patients where systemic infec-
tion may result. Systemic fungal disease due to S. cerevisiae
has been recorded occasionally and is most frequently found
in severely ill patients and may be a contributer to, or in
some cases the main cause of, death. S. cerevisiae has been
implicated in pneumonia in a HIV patient, and the pres-
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ence of this organism in a number of organs at autopsy was
recorded, leading to the suggestion that the yeast first col-
onized the oropharynx of the immunocompromised host and
was then aspirated to the lungs, where it entered the blood-
stream and spread hematogenously to the spleen and small
intestine [16].
In three cases of invasive infections with S. cerevisiae,
pneumonia, liver abscess and sepsis, and systemic infection
were attributed to the presence of this yeast [17]. S. cerevi-
siae was isolated from a number of organs and from sites
that would normally be regarded as sterile, indicating that
pathogenic isolates of this yeast are capable of tissue inva-
sion and dissemination. A female patient who underwent
bone marrow transplantation (BMT) developed a fever, and
blood cultures revealed the presence of S. cerevisiae [18].
Although this is the sole reference to S. cerevisiae infection
in BMT patients, it does indicate that this yeast is capable of
infecting patients immunocompromised as a result of ther-
apeutic procedures. S. cerevisiae septicemia in a patient
with preleukemic hemopathy may have been responsible for
death [19], and S. cerevisiae has also been associated with
cases of septicemia [20] and postoperative peritonitis [21].
While the involvement of S. cerevisiae in a range of super-
ficial and systemic diseases has been well documented,
there is some evidence to suggest that the yeast may also
play a role in the induction of Crohn’s disease. Elevated
levels of IgG and IgA antibodies to S. cerevisiae have been
detected in patients affected by Crohn’s disease, but any
involvement of this yeast in the etiology of this condition
remains to be clarified [22].
S. cerevisiae has been implicated in a range of diseases in
geriatric patients and those immunocompromised as a result
of disease. The number of cases of infection by this yeast in
such patients is still relatively low, especially when com-
pared to cases caused by C. albicans, but the salient fact is
that infection is caused by what was previously regarded as
a nonpathogen. In one case, a patient was admitted to the
hospital for hypotension, shortness of breath, and chest
pain. The patient had a number of predisposing factors and
was on a “health diet” consisting of a large daily intake of
vitamins and brewer’s yeast. S. cerevisiae was isolated from
the lungs, and the ingestion of baker’s yeast was identified
as the source of infection [23]. The ingestion of brewer’s
yeast has previously been associated with fever [24]. In
addition to entry via the oropharynx, gastrointestinal tract,
and indwelling cathethers, the ingestion of food contami-
nated with S. cerevisiae is considered a potential source of
infection in BMT patients [18].
The yeast Saccharomyces bouladrii (nom. inval) has
been administered for the treatment of severe cases of di-
arrhea but cannot be genotypically distinguished from S.
cerevisiae [25], and a number of cases of fungemia have
been documented following the use of this yeast to control
diarrhea. Analysis of commercially available strains of S.
boulardii has revealed moderate virulence levels when
tested in murine models of systemic infection [13]. Conse-
quently, caution is recommended when using this yeast to
control this condition in severely ill or immunocompro-
mised patients.
5. Virulence attributes of pathogenic S. cerevisiae
isolates
Virulent isolates have been defined as those isolates of S.
cerevisiae that are capable of growth at 42°C [26]. This is
considered an important characteristic as febrile patients can
manifest this temperature, and any organism that can sur-
vive and grow at this elevated temperature would have an
inherent advantage. In an examination of a range of labo-
ratory and industrial strains of S. cerevisiae, growth was
observed over the range 37–40°C, but only virulent isolates
were capable of growth at 42°C. The ability to grow at this
temperature appears to be critical to the virulence of S.
cerevisiae and seems to be polygenic in nature. Some clin-
ical isolates also demonstrate the ability to produce and
secrete proteinase, as determined by the ability to liquefy
gelatin and hydrolyse casein. The pathogenic yeast C. albi-
cans can also secrete proteinases that have been implicated
in the degradation of immunoglobulin A (IgA), an impor-
tant element of the host’s immune response to infection by
this yeast [27]. Virulent isolates may grow as pseudohyphae
under certain conditions, and pseudohyphae have been seen
to penetrate agar, which may give an indication of their role
in vivo [28]. Pseudohyphal growth was not observed in
nonclinical isolates of S. cerevisiae, and this ability may be
important in the penetration of host tissue by virulent iso-
lates and could play a role in the blocking of capillaries
associated with animal mortality [29].
Clinical isolates of S. cerevisiae persisted in the brains of
CD-1 mice for up to 7 days, but nonclinical isolates were
cleared, indicating that pathogenic isolates can grow and
avoid clearance in immunocompromized animals [29].
Complement factor five-deficient mice were inoculated in-
travenously, and the presence of S. cerevisiae in the brain,
spleen, liver, kidney, and lung was recorded. By using this
model system, S. cerevisiae isolates were differentiated into
four categories on the basis of tissue penetration, persis-
tence, and mortality [8]. One group of isolates gave a
mortality rate in excess of 80%, and the second produced an
intermediate mortality rate (30–80%). The third class of
isolates were described as being of low virulence; they
produced low or negligible mortality but did proliferate to
high levels in the brain. The fourth class were deemed to be
nonvirulent, did not kill, and did not persist for long periods
in inoculated animals. The persistence of the yeasts in the
brain, spleen, liver, kidneys, and lungs depended upon the
nature of the isolate (virulent vs. nonvirulent) but many
were still present at certain body sites 14 days postinfection,
indicating the ability of this yeast to perisist for long periods
in immunodeficient animals and grow in environments that
it would not normally encounter.
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Phenotypic switching is a well-characterized phenome-
non in the pathogenic yeast C. albicans where it has been
implicated in the generation of variant phenotypes in infect-
ing populations [30,31]. This phenomenon has also been
observed in virulent isolates of S. cerevisiae where it occurs
at a high frequency and does not require mutagenesis [32].
It is different from the well characterized phenotypic switch
seen in S. cerevisiae (grande/petite) in that it is reversible
and occurs at a high frequency. It may act as a virulence
factor in that it allows the rapid generation of variant phe-
notypes in an infecting population, but the role of pheno-
typic switching in the virulence of S. cerevisiae has yet to be
established. Some clinical isolates have demonstrated the
ability to flocculate under in vitro conditions, and this may
constitute a virulence factor in that it could lead to the
obstruction of capillaries; however, no clear correlation
with pathogenicity has yet been established [8]. The role of
heat-shock proteins in the pathogenesis of S. cerevisiae has
been investigated, and it has been established that overex-
pression of heat-shock protein 90 increases virulence in
mice [33]. This protein is an immunodominant antigen and
is associated with protective humoral immunity.
In summary, virulent isolates of S. cerevisiae manifest a
number of characteristics which are essential for their
pathogenicity in the human host. They are capable of pro-
liferating within the host, particularly if the host is immu-
nocompromised as a result of therapy or disease, and may
persist for prolonged periods of time in susceptible hosts.
Virulent isolates have also been shown to be capable of
dissemination from the site of entry and of invading tissue.
6. Therapy for the control of S. cerevisiae disease
There are two major classes of antifungal agents: the
polyenes and the azoles. Amphotericin B desoxycholate is
the primary polyene for use against fungal infections and is
produced by the Streptomyces. It is quite similar to a phos-
pholipid in structure and length except that it contains a
polyene hydrocarbon backbone as well as a polyhydroxyl
backbone [34]. The drug is poorly soluble in water [35] due
to the opposite polarities of the hydroxyls and hydrocarbons
[34] and is conventionally dissolved in sodium desoxy-
cholate solution [36], leading to the production of ribbon-
like micelles.
The azole class of antifungal agents are synthetic drugs
not found in nature. They contain three azole groupings and
act by inhibiting ergosterol biosynthesis, which is achieved
by blocking the conversion of lanosterol to 14-demethyl-
lanosterol and leads to the accumulation of ergosterol pre-
cursors [37] and subsequent disruption of membrane integ-
rity. Therapy with azoles can be orally or topically
administered [11].
In a number of cases where amphotericin B desoxy-
cholate was successfully used to treat S. cerevisiae infec-
tion, all but one resulted in the cure of disease [16,17].
Amphotericin B was used to treat S. cerevisiae found in the
lung, blood, urine, and in a liver abscess, indicating the
usefulness of the drug in treating infections in a wide range
of anatomical areas. On this basis, it was recommended that
amphotericin B should be the treatment of choice for S.
cerevisiae infection [17]. However, as has previously been
noted, S. cerevisiae infection has been particularly associ-
ated with immunocompromised individuals. Amphotericin
B is a very powerful antifungal agent that has been in use
for over 40 years, but its usefulness is limited due to its well
documented adverse effects on the renal system [38–41].
Amphotericin B functions by binding to sterols in the cell,
and its efficacy is achieved by its affinity for ergosterol in
fungal cell membranes causing pore formation and leakage
of the cells’ contents. It is believed that the binding of the
drug to cholesterol in mammalian cell membranes [38] is
responsible for amphotericin B toxicity. The renally toxic
nature of amphotericin B precludes many individuals from
receiving it and also causes many others to cease therapy
due to side effects. Infusion-related side-effects, such as
chills and fevers, are usually resolvable through clinical
management [38,41]. Renal side-effects include inability to
concentrate urine (leading to electrolytic imbalance), caus-
ing either dose reduction or termination of the therapy [41].
Renal tubular damage is also quite common and severe
[40,41].
Amphotericin B is not always an option in treating Sac-
charomyces infection due to the adverse side effects asso-
ciated with its use, but many other agents, particularly the
azole antifungals, have been used to treat such infections.
Fluconazole has become the treatment of choice for many
types of Candida infections. In one case report, the use of
150 mg/day of fluconazole cured a patient with Saccharo-
myces infection [18]. Previously, however, outright resis-
tance to fluconazole during in vitro antimycotic testing was
recorded [9]. These results were borne out by the use of
fluconazole in the treatment of a 38-year-old female patient
with S. cerevisiae vaginitis. This patient was treated with
200 mg/day for 7 days. This therapy failed, and the patient
went into remission following treatment with clotrimazole
100 mg/day followed by 500 mg/week. There was prompt
clinical response during the first 7 days of clotrimazole
treatment in contrast with the fluconazole treatment.
Clotrimazole therapy led to cure in two cases of Saccha-
romyces disease [9], but the response in both cases was
slow, and eradication of the yeast occurred only after pro-
longed therapy. Ketoconazole at 400 mg/day for 14 days
was then used to eradicate the yeast after cultures were
found to be positive. This treatment failed, and clotrimazole
was again used at 100 mg/day until total eradication was
achieved. Follow-up therapy of clotrimazole at 500 mg/
week eventually led to remission.
Ketoconazole has been used to treat S. cerevisiae infec-
tions with varying rates of success. Ketoconazole (200 mg)
was administered orally, twice daily, along with two anti-
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bacterial agents to treat serious pleural effusion [23] but the
patient died of acute respiratory failure on the sixth day after
hospital admission. Due to the severe nature of the patient’s
condition and the bacterial complications involved, it would
be unwise to imply from this study that ketoconazole is not
suitable for treatment of S. cerevisiae infection. A number
of cases cited in the literature support ketoconazole usage
against S. cerevisiae and indicate cure of patients infected
with S. cerevisiae located in the urine and the peritoneum
[17]. The eradication of S. cerevisiae from the urinary tract
was unusual, because ketoconazole is not excreted in the
active form. Ketoconazole has been used successfully in the
treatment of S. cerevisiae vaginitis [9]. In one example, a
regime of 400 mg/day for 14 days followed by 200 mg/day
led to remission of acute symptomatic S. cerevisiae vulvo-
vaginitis. In another case, ketoconazole combined with bo-
ric acid (600 mg/day) led to eradication. A 66-year-old male
suffering from pancreatic cancer with S. cerevisiae disease
died after failing to complete ketoconazole therapy [16]. It
would seem that susceptibility of S. cerevisiae to ketocon-
azole is either strain dependent or dependent on the body
site in which the yeast is located.
The use of boric acid, particularly as a suppository, led to
the eradication of S. cerevisiae when used against two
isolates obtained from patients with symptomatic vulvovag-
initis [9]. In the first case, boric acid at 600 mg/day was used
in combination with ketoconazole (400 mg/day), leading to
eradication. In the second case, boric acid (600 mg twice
daily) was the only therapy employed and led to eradication
of S. cerevisiae. Boric acid suppositories were used with
varying degrees of success: in two cases, mycological cure
was reported with symptom improvement for one individ-
ual, but symptom persistence for the second, and a third
case resulted in mycological and symptom remission [12].
Two other azoles should receive mention. Two doses of
tioconazole resulted in symptom relief of a 48-year-old
woman presenting with vaginitis [12]. The second triazole,
voriconazole (UK-109,496), has been tested in vitro against
S. cerevisiae [42] and had an in vitro minimal inhibitory
concentration50 (MIC50) value of 0.12 g/ml compared to
fluconazole MIC50 value of 2 g/ml. There are no reports of
its use against S. cerevisiae infection in the clinical litera-
ture.
The use of combination therapy is recommended for the
eradication of S. cerevisiae-induced disease [43] as is pro-
longed therapy [9]. In conclusion, amphotericin B should be
considered the treatment of choice for serious S. cerevisiae
infection [17,42] except where underlying conditions pre-
clude its use. In cases where amphotericin B therapy is not
advised, prolonged treatment with either clotrimazole sup-
positories, boric acid suppositories, or oral ketoconazole is
advised [9]. The use of liposomal forms of amphotericin B
should also be considered, especially in cases where infec-
tion is severe and triazole therapy has failed.
7. Drug resistance in pathogenic S. cerevisiae isolates
A range of antifungal agents have been used to treat S.
cerevisiae infections and, in many cases, therapy has been
unsuccessful. Underlying disease is possibly a factor pre-
venting successful therapy [23]. The worldwide spread of
HIV infection has brought about a large population of in-
dividuals susceptible to a wide variety of organisms, many
of which had previously been regarded as nonpathogenic
[44]. During the late 1980s and early 1990s, it was noted
that many emerging fungal pathogens such as Fusarium and
Trichosporon species [44] and Candida krusei [45] showed
inherent resistance to certain antifungals.
The resistance of S. cerevisiae to antifungals has been
cited in a number of cases [9,17,43]. Fluconazole has been
regarded as the treatment of choice for C. albicans infec-
tions for many years, although AIDS-associated oropharyn-
geal isolates now show increasing signs of resistance [46].
S. cerevisiae has been noted for its resistance to certain
drugs, notably fluconazole [9]. In an antifungal susceptibil-
ity study, fluconazole resistance in urinary tract S. cerevi-
siae infection was noted [43]. A high MIC value for flu-
conazole (2 g/ml) against S. cerevisiae compared to both
amphotericin B and flucytosine was observed. A study by
Espinel–Ingroff [42] also noted an MIC50 value of 2 g/ml
for S. cerevisiae compared to MIC50 of 0.5 g/ml for C.
albicans. The inherent resistance to fluconazole highlights
the importance of the correct identification of the yeast
species in clinical cases in order to provide appropriate
therapy.
The S. cerevisiae genome contains genes designated as
multidrug resistance genes [47]. It has been established that
dominant mutations in the Cys6 zinc finger transcription
factors PDR1 and PDR3 brings about an increased resis-
tance to a number of agents [47]. These factors are respon-
sible for the activation of an adenosine 5-triphosphate bind-
ing cassette transporter protein-encoding gene PDR5.
Transcription of this gene product is required for cyclohex-
imide resistance. The PDR1 and PDR3 gene products also
positively regulate YOR1 resistance. YOR1 is an oligomy-
cin-resistance gene whose promoter region contains a
PDRE (PDR1/PDR3 response element) 215 bp upstream of
the transcription start site. The PDRE site is one of two
positive regulators of this gene. Another positive regulatory
site and a negative regulatory site also exist but are acted
upon by, as yet, unidentified factors [47]. The PDR5 gene
contains an identical PDRE sequence to that found in YOR1
and also acts as a positive regulator for transcription. The
PDRE found in YOR1 must be fully functional in order for
oligomycin tolerance to be conferred on the yeast.
The mechanism of fluconazole tolerance/resistance em-
ployed by S. cerevisiae is poorly characterized, but it is
possible that there are other undiscovered multidrug resis-
tance genes. One way to analyze the likely mechanisms
involved is to look at a yeast in which fluconazole resistance
mechanisms have been well documented. One such yeast is
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C. krusei. The advent of HIV infection and widespread use
of triazole antifungals have contributed to the increase in C.
krusei infections [45]. This is due to the high inherent level
of resistance to triazoles found in C. krusei [37,44,45].
There are three general methods of resistance found in
Candida species. First, fluconazole targets the enzyme 14-
demethylase. Alteration of this enzyme stops the build-up of
C14-methylated sterols, therefore removing the possibility
of membrane disruption. The second method is by de-
creased uptake of the drug or increased efflux, and third, a
deficiency in C5(6) desaturase leading to production of 14-
methylfecosterol, which does not affect yeast viability,
when 14-demethylase is inhibited. One study determined
that the predominant sterol in C. krusei is ergosterol and that
fluconazole inhibits 14-demethylase [37]. It was estab-
lished that C. krusei fluconazole resistance was mediated by
reduced susceptibility of 14-demethylase. It remains un-
clear which of these resistance mechanisms apply in S.
cerevisiae. Until further studies are conducted, fluconazole
resistance will remain a problem, as will therapy for S.
cerevisiae disease in general.
8. Implications for biotechnology
Although classically considered to be nonpathogenic, S.
cerevisiae is now emerging as a cause of disease in immu-
nocompromised patients [7–9]. A number of the virulence
factors associated with clinical isolates of this yeast have
been identified and partly characterized. It is generally
agreed that the factors already described are only part of the
overall complement of such factors, and the role of these in
the pathogenicity of this yeast is poorly understood [26].
The work cited here indicates that differentiation of yeasts
into rigidly defined classes of pathogen and nonpathogen is
incorrect. It would appear that a continuum exists between
these two categories, and that to consider a yeast such as S.
cerevisiae as always nonpathogenic is invalid. Although it
may not be as virulent as C. albicans, some isolates are
capable of causing disease and persisting in the host for
prolonged periods, particularly in cases of immunocompro-
mization, long-term hospitalization, or prolonged broad-
spectrum antibiotic use.
With the identification of the pathogenic potential of S.
cerevisiae, certain circumstances may preclude the use of
this yeast, particularly where immunocompromised individ-
uals may be exposed for prolonged periods. There is ample
evidence to suggest that infection by S. cerevisiae may
result from ingestion of yeast tablets [23,24], from baking
[13], or from associating with individuals who work in close
contact with the yeast [12]. Caution needs to be exercised by
those working in the industrial and biotechnological sectors
to ensure that S. cerevisiae is treated as a potential pathogen.
Consumers and those in the medical profession should also
be alerted to the dangers of immunocompromised individ-
uals ingesting brewer’s yeast tablets as part of health diets
[10,18,24].
It is conceivable that potentially pathogenic isolates of S.
cerevisiae are currently in use in industrial or biotechnolog-
ical processes. The ability to distinguish pathogenic from
nonpathogenic strains would be of great benefit to commer-
cial users of S. cerevisiae, and a number of simple tests may
be employed to assist this process. The ability to grow at
42°C is considered to be a crucial characteristic of patho-
genic isolates of S. cerevisiae [28]. Many clinical isolates
are capable of pseudohyphal growth, of producing protein-
ase, and are capable of phenotypic switching [32]. Many
industrially important strains of S. cerevisiae are also capa-
ble of growth at elevated temperatures (e.g. 40°C) and of
producing pseudohyphae [48], so it is conceivable that such
strains, if introduced into a suitably immunocompromised
host, could result in disease.
While the identification of possible pathogenic isolates
may be accomplished in the laboratory, definitive proof of a
strain’s pathogenic potential would require in vivo testing.
9. Conclusion
Although widely used for the production of bread and
alcoholic beverages for thousands of years, S. cerevisiae is
now being identified as an opportunistic pathogen in a
number of cases. Those most at risk appear to be immuno-
compromised individuals but also patients showing no ob-
vious predisposing factor and those working with the yeast
on a regular basis. Although those isolates that have been
implicated in disease have a number of clearly defined
virulence characteristics, there remains the possibility that
yeasts used industrially may have some or all of these
factors and so could pose a potential risk to susceptible
hosts. In light of the recognition of the pathogenicity of S.
cerevisiae, industrialists and biotechnologists would be
wise to exercise caution when dealing with this yeast, and
ensure that it is treated as a potential pathogen rather than as
a nonpathogenic yeast.
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